TickerKhojComparison · NSE · data 2026-11-02
Corona Remedies Limited vs NATCO Pharma Limited
In plain words
Size: NATCO Pharma Limited is about 1.2 times the market value of Corona Remedies Limited.
Valuation (P/E): Corona Remedies Limited 65.1 vs NATCO Pharma Limited 12.4.
Return on equity: Corona Remedies Limited 27.4% vs NATCO Pharma Limited 16.9%.
Profit growth over 3 years: Corona Remedies Limited 29.7% a year vs NATCO Pharma Limited 25.6% a year.
Debt to equity: Corona Remedies Limited 0.22 vs NATCO Pharma Limited 0.08.
Differences in the numbers, not a recommendation of either stock.
Side by side
| CORONA | NATCOPHARM | |
|---|---|---|
| Price | ₹2,201.9 | ₹784.7 |
| Market cap | ₹13,125 cr | ₹15,350 cr |
| P/E | 65.1 | 12.4 |
| P/B | 16.7 | — |
| ROE | 27.4% | 16.9% |
| ROCE | 32.4% | 15.6% |
| Debt / equity | 0.22 | 0.08 |
| Operating margin | 18.4% | 24.6% |
| Dividend yield | 0.47% | 0.57% |
| Sales growth, 3 years (yearly) | 16.6% | 14.5% |
| Profit growth, 3 years (yearly) | 29.7% | 25.6% |
| 1-year return | 49.9% | -5.1% |
| Revenue, last 12 months | ₹1,559 cr | ₹3,485 cr |
| Net profit, last 12 months | ₹207 cr | ₹1,144 cr |
| Latest quarter | Sept 2026 | Jun 2026 |
| Quarter net profit | ₹60 cr | ₹207 cr |
| Quarter profit vs a year earlier | +15.3% | -57.0% |
| Promoter holding | 69.00% | 49.39% |
| Health check | Strong (7.4/10) | Strong (6.8/10) |
Common questions
Which has a higher P/E, Corona Remedies Limited or NATCO Pharma Limited?
Corona Remedies Limited trades at the higher P/E (65.1 against 12.4). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
Corona Remedies Limited (27.4% against 16.9%).
Which carries more debt?
Corona Remedies Limited has the higher debt-to-equity ratio (0.22 against 0.08).